



Experimental, Investigational, or Unproven Services

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Experimental, Investigational, or Unproven Services	1
Summary	1
Definitions	2
Clinical Exclusions or Experimental, Investigational, or Unproven	3
Clinical Guideline Revision / History Information	33

Summary

The services referenced in this Clinical Guideline are considered experimental, investigational, or unproven and are therefore not covered by the Plan. This Clinical Guideline may not encompass all services specific benefit plan documents (e.g., Evidence of Coverage, Schedule of Benefits) and federal or state mandated health benefits and laws supersede this Clinical Guideline. The member's benefit plan documents specify the services that are covered, excluded, or subject to limitations.

A service is considered experimental, investigational, or unproven when its safety and efficacy have not been established. These interventions may yield outcomes that are inferior to standard medical treatments with proven long-term clinical utility. To determine whether a service, device, treatment, or procedure has proven safety and efficacy, a thorough review of the available reliable evidence is conducted. This evidence may include, but is not limited to the following sources (listed in order of decreasing reliability):

1. Published technology assessments and/or high-quality meta-analyses
2. Randomized, controlled trials (RCTs)
3. Other controlled studies, such as non-randomized controlled trials, and cohort studies
4. Case reports or case series
5. Reports of expert opinion and consensus statements from professional organizations

Definitions

“Experimental, investigational, or unproven services” include any drug, biologic, device, diagnostic, product, equipment, procedure, treatment, supply, or other service used in or directly related to the diagnosis, evaluation, or treatment of a disease, injury, illness, or other health condition for which one or more of the following criteria apply when the service is rendered with respect to the use for which benefits are sought:

- The drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply cannot be legally marketed in the United States without the final approval of the Food and Drug Administration (“FDA”), or other licensing or regulatory agency, and such final approval has not been granted;
- The FDA has determined the drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply to be contraindicated for the specific use;
- The drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply is provided as part of a clinical research protocol or clinical trial or is provided in any other manner that is intended to evaluate the safety, toxicity, or efficacy of the drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply;
- The drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply is subject to review and approval of an Institutional Review Board (“IRB”) or other body serving a similar function;
- The drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply is provided pursuant to informed consent documents that describe the drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply as Experimental/Investigational, or otherwise indicate that the safety, toxicity, or efficacy of the drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply is under evaluation.

“Off-label use” refers to the use of an FDA-approved drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply for a purpose, condition, or patient population other than those for which it has received FDA approval. Off-label use may be considered experimental or investigational, depending on the available evidence supporting its safety and efficacy for the specific use in question.

“Peer review” refers to the evaluation process in which experts in a relevant field critically assess the quality, validity, and reliability of a research study or publication. Peer review helps ensure that only

scientifically sound and credible evidence is considered in the development of clinical policies and guidelines.

“Standard medical treatment” refers to any healthcare service, treatment, procedure, facility, equipment, drug, device, or supply that is in general use in the medical community in the United States, and:

- Has been demonstrated through reliable evidence in peer-reviewed medical literature to have scientifically established medical value for diagnosing, curing or alleviating the condition being treated; *and*
- Is appropriate for the hospital or other facility provider in which it is performed; *and*
- The performing physician or other professional provider has had the appropriate training and experience to provide the service, treatment or procedure.

“Reliable evidence” means reports and articles with scientifically valid data published in authoritative, peer-reviewed medical and scientific literature. Reports, articles, or statements by providers or groups of providers that only contain abstracts, anecdotal evidence or personal professional opinions are not considered reliable evidence.

Clinical Exclusions or Experimental, Investigational, or Unproven

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0002M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and alcoholic steatohepatitis (ASH)	10/11/2017	11/02/2026
0003M	Liver disease, ten biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, haptoglobin, AST, glucose, total cholesterol and triglycerides) utilizing serum, prognostic algorithm reported as quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH)	10/11/2017	11/02/2026
0004M	Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score	10/11/2017	11/02/2026
0015M	Adrenal cortical tumor, biochemical assay of 25 steroid markers, utilizing 24-hour urine specimen and clinical parameters, prognostic algorithm reported as a clinical risk and integrated clinical steroid risk for adrenal cortical carcinoma, adenoma, or other adrenal malignancy	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0016M	Oncology (bladder), mRNA, microarray gene expression profiling of 219 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like)	5/02/2023	11/02/2026
0017M	Oncology (diffuse large B-cell lymphoma [DLBCL]), mRNA, gene expression profiling by fluorescent probe hybridization of 20 genes, formalin-fixed paraffin-embedded tissue, algorithm reported as cell of origin	5/02/2023	11/02/2026
0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed	7/21/2020	11/02/2026
0263T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest	7/21/2020	11/02/2026
0440T	Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve	7/21/2020	11/02/2026
0441T	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve	7/21/2020	11/02/2026
0481T	Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed	7/21/2020	11/02/2026
0673T	Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance	11/01/2024	11/02/2026
0716T	Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score	11/02/2026	11/02/2026
0002U	Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps	1/18/2018	11/02/2026
0003U	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0005U	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score	1/18/2018	11/02/2026
0007U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service	1/18/2018	11/02/2026
0008U	Helicobacter pylori detection and antibiotic resistance, DNA, 16S and 23S rRNA, gyrA, pbp1, rdxA and rpoB, next-generation sequencing, formalin-fixed paraffin-embedded or fresh tissue or fecal sample, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline, and rifabutin	5/02/2023	11/02/2026
0009U	Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non-amplified	5/02/2023	11/02/2026
0010U	Infectious disease (bacterial), strain typing by whole genome sequencing, phylogenetic-based report of strain relatedness, per submitted isolate	5/02/2023	11/02/2026
0011U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites	1/18/2018	11/02/2026
0019U	Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents	5/02/2023	11/02/2026
0055U	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma	5/02/2023	11/02/2026
0061U	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO ₂], oxyhemoglobin [ctHbO ₂], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0067U	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score	5/02/2023	11/02/2026
0069U	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score	5/02/2023	11/02/2026
0079U	Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification	5/02/2023	11/02/2026
0086U	Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility	5/02/2023	11/02/2026
0087U	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score	5/02/2023	11/02/2026
0088U	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection	5/02/2023	11/02/2026
0089U	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)	5/02/2023	11/02/2026
0090U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	5/02/2023	11/02/2026
0094U	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0108U	Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer	11/01/2024	11/02/2026
0109U	Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species (A. fumigatus, A. terreus, A. niger, and A. flavus), blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species	5/02/2023	11/02/2026
0112U	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene	5/02/2023	11/02/2026
0113U	Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score	5/02/2023	11/02/2026
0114U	Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus	11/02/2026	11/02/2026
0118U	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA	5/02/2023	11/02/2026
0120U	Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter	5/02/2023	11/02/2026
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, plasma, untargeted next-generation sequencing, report for significant positive pathogens	5/02/2023	11/02/2026
0153U	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0156U	Copy number (eg, intellectual disability, dysmorphology), sequence analysis	5/02/2023	11/02/2026
0170U	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis	5/02/2023	11/02/2026
0203U	Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness	5/02/2023	11/02/2026
0205U	Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements	5/02/2023	11/02/2026
0206U	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease	5/02/2023	11/02/2026
0207U	Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)	5/02/2023	11/02/2026
0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities	5/02/2023	11/02/2026
0220U	Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score	5/02/2023	11/02/2026
0228U	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0243U	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia	5/02/2023	11/02/2026
0247U	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth	5/02/2023	11/02/2026
0253U	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)	5/02/2023	11/02/2026
0254U	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy, per embryo tested	5/02/2023	11/02/2026
0255U	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score	5/02/2023	11/02/2026
0256U	Trimethylamine/trimethylamine N-oxide (TMA/TMAO) profile, tandem mass spectrometry (MS/MS), urine, with algorithmic analysis and interpretive report	5/02/2023	11/02/2026
0258U	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics	5/02/2023	11/02/2026
0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	5/02/2023	11/02/2026
0262U	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0264U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	5/02/2023	11/02/2026
0266U	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes	5/02/2023	11/02/2026
0279U	Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen III binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen III binding	5/02/2023	11/02/2026
0280U	Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen IV binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen IV binding	5/02/2023	11/02/2026
0281U	Hematology (von Willebrand disease [VWD]), von Willebrand propeptide, enzyme-linked immunosorbent assays (ELISA), plasma, diagnostic report of von Willebrand factor (VWF) propeptide antigen level	5/02/2023	11/02/2026
0282U	Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes	11/01/2024	11/02/2026
0285U	Oncology, disease progression and response monitoring to radiation, chemotherapy, or other systematic cancer treatments, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported in ng/mL	4/25/2022	11/02/2026
0288U	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score	4/25/2022	11/02/2026
0289U	Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score	4/25/2022	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0290U	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score	4/25/2022	11/02/2026
0291U	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score	4/25/2022	11/02/2026
0292U	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score	4/25/2022	11/02/2026
0293U	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score	4/25/2022	11/02/2026
0294U	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score	4/25/2022	11/02/2026
0296U	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy	4/25/2022	11/02/2026
0297U	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification	4/25/2022	11/02/2026
0298U	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	4/25/2022	11/02/2026
0299U	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	4/25/2022	11/02/2026
0300U	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	4/25/2022	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0301U	Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR)	5/02/2023	11/02/2026
0302U	Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); following liquid enhancement	5/02/2023	11/02/2026
0303U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic	5/02/2023	11/02/2026
0304U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic	5/02/2023	11/02/2026
0305U	Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index	5/02/2023	11/02/2026
0306U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD	4/25/2022	11/02/2026
0307U	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD	4/25/2022	11/02/2026
0308U	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]) with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD	5/02/2023	11/02/2026
0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event	5/02/2023	11/02/2026
0310U	Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0311U	Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified	4/25/2022	11/02/2026
0312U	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment	5/02/2023	11/02/2026
0313U	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)	4/25/2022	11/02/2026
0314U	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	4/25/2022	11/02/2026
0315U	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)	4/25/2022	11/02/2026
0316U	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine	5/02/2023	11/02/2026
0317U	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm generated evaluation reported as decreased or increased risk for lung cancer	4/25/2022	11/02/2026
0318U	Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood	4/25/2022	11/02/2026
0319U	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection	4/25/2022	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0320U	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection	4/25/2022	11/02/2026
0321U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique	4/25/2022	11/02/2026
0322U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD	5/02/2023	11/02/2026
0323U	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites, or fungi	4/25/2022	11/02/2026
0328U	Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient-adverse event, per date of service	5/02/2023	11/02/2026
0329U	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations	4/25/2022	11/02/2026
0330U	Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab	4/25/2022	11/02/2026
0331U	Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alternations	4/25/2022	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0332U	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy	5/02/2023	11/02/2026
0333U	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm reported as normal or abnormal result	5/02/2023	11/02/2026
0335U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants	5/02/2023	11/02/2026
0336U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent)	5/02/2023	11/02/2026
0342U	Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline	5/02/2023	11/02/2026
0343U	Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0344U	Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH	5/02/2023	11/02/2026
0347U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes	5/02/2023	11/02/2026
0348U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes	5/02/2023	11/02/2026
0349U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions	5/02/2023	11/02/2026
0350U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes	5/02/2023	11/02/2026
0351U	Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein, serum, algorithm reported as likelihood of bacterial infection	5/02/2023	11/02/2026
0355U	APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2)	5/02/2023	11/02/2026
0356U	Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence	11/02/2026	11/02/2026
0362U	Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes	5/02/2023	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
0371U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine	11/01/2024	11/02/2026
0372U	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score	11/01/2024	11/02/2026
0454U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	11/02/2026	11/02/2026
0540U	Transplantation medicine, quantification of donor-derived cell-free DNA using next-generation sequencing analysis of plasma, reported as percentage of donor-derived cell-free DNA to determine probability of rejection	11/02/2026	11/02/2026
19105	Ablation, cryosurgical, of fibroadenoma, including ultrasound guidance, each fibroadenoma	1/18/2018	11/02/2026
20560	Needle insertion(s) without injection(s); 1 or 2 muscle(s)	4/27/2020	11/02/2026
20561	Needle insertion(s) without injection(s); 3 or more muscles	4/27/2020	11/02/2026
22867	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; single level	1/18/2018	11/02/2026
22868	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure)	1/18/2018	11/02/2026
22869	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
22870	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code for primary procedure)	1/18/2018	11/02/2026
31660	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe	1/18/2018	11/02/2026
31661	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes	1/18/2018	11/02/2026
33289	Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed	4/27/2020	11/02/2026
41512	Tongue base suspension, permanent suture technique	4/11/2017	11/02/2026
41530	Submucosal ablation of the tongue base, radiofrequency, 1 or more sites, per session	4/11/2017	11/02/2026
43206	Esophagoscopy, flexible, transoral; with optical endomicroscopy	1/18/2018	11/02/2026
43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed	1/18/2018	11/02/2026
43252	Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy	4/11/2017	11/02/2026
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed	1/18/2018	11/02/2026
43285	Removal of esophageal sphincter augmentation device	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
43257	Esophagogastroduodenoscopy, flexible, transoral; with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease	4/11/2017	11/02/2026
46707	Repair of anorectal fistula with plug (eg, porcine small intestine submucosa [SIS])	4/11/2017	11/02/2026
53451	Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance	5/02/2023	11/02/2026
53452	Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance	5/02/2023	11/02/2026
53453	Periurethral transperineal adjustable balloon continence device; removal, each balloon	5/02/2023	11/02/2026
53454	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume	5/02/2023	11/02/2026
53860	Transurethral radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence	1/18/2018	11/02/2026
61630	Balloon angioplasty, intracranial (eg, atherosclerotic stenosis), percutaneous	4/11/2017	11/02/2026
62263	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days	1/18/2018	11/02/2026
62264	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
62287	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar	1/18/2018	11/02/2026
62291	Injection procedure for discography, each level; cervical or thoracic	1/18/2018	11/02/2026
62292	Injection procedure for chemonucleolysis, including discography, intervertebral disc, single or multiple levels, lumbar	1/18/2018	11/02/2026
64630	Destruction by neurolytic agent; pudendal nerve	1/18/2018	11/02/2026
64654	Initial open implantation of baroreflex activation therapy (BAT) modulation system, including lead placement onto the carotid sinus, lead tunnelling, connection to a pulse generator placed in a distant subcutaneous pocket (ie, total system), and intraoperative interrogation and programming	11/02/2026	11/02/2026
64655	Revision or replacement of baroreflex activation therapy (BAT) modulation system, with intraoperative interrogation and programming; lead only	11/02/2026	11/02/2026
64656	Revision or replacement of baroreflex activation therapy (BAT) modulation system, with intraoperative interrogation and programming; pulse generator only	11/02/2026	11/02/2026
64657	Removal of baroreflex activation therapy (BAT) modulation system; total system, including lead and pulse generator	11/02/2026	11/02/2026
64658	Removal of baroreflex activation therapy (BAT) modulation system; lead only	11/02/2026	11/02/2026
64659	Removal of baroreflex activation therapy (BAT) modulation system; pulse generator only	11/02/2026	11/02/2026
72285	Discography, cervical or thoracic, radiological supervision and interpretation	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
76977	Ultrasound bone density measurement and interpretation, peripheral site(s), any method	4/11/2017	11/02/2026
77605	Hyperthermia, externally generated; deep (ie, heating to depths greater than 4 cm)	1/18/2018	11/02/2026
77610	Hyperthermia generated by interstitial probe(s); 5 or fewer interstitial applicators	1/18/2018	11/02/2026
77615	Hyperthermia generated by interstitial probe(s); more than 5 interstitial applicators	1/18/2018	11/02/2026
78350	Bone density (bone mineral content) study, 1 or more sites; single photon absorptiometry	1/18/2018	11/02/2026
78351	Bone density (bone mineral content) study, 1 or more sites; dual photon absorptiometry, 1 or more sites	1/18/2018	11/02/2026
81291	MTHFR (5,10-methylenetetrahydrofolate reductase) (eg, hereditary hypercoagulability) gene analysis, common variants (eg, 677T, 1298C) [Healthy Weight DNA Insight; PGxOne Plus (Admera Health)]	4/11/2017	11/02/2026
81350	UGT1A1 (UDP glucuronosyltransferase 1 family, polypeptide A1) (eg, irinotecan metabolism), gene analysis, common variants (eg, *28, *36, *37)	1/18/2018	11/02/2026
81355	VKORC1 (vitamin K epoxide reductase complex, subunit 1) (eg, warfarin metabolism), gene analysis, common variant(s) (eg, -1639G>A, c.173+1000C>T)	10/11/2017	11/02/2026
81427	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)	10/11/2017	11/02/2026
81440	Nuclear encoded mitochondrial genes (eg, neurologic or myopathic phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP	10/11/2017	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
81449	Solid organ neoplasm, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants and copy number variants or rearrangements, if performed; RNA analysis	11/01/2025	11/02/2026
81451	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	11/01/2025	11/02/2026
81456	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	11/01/2025	11/02/2026
81460	Whole mitochondrial genome (eg, Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and retinitis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection	10/11/2017	11/02/2026
81465	Whole mitochondrial genome large deletion analysis panel (eg, Kearns-Sayre syndrome, chronic progressive external ophthalmoplegia), including heteroplasmy detection, if performed	10/11/2017	11/02/2026
81470	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2	10/11/2017	11/02/2026
81471	X-linked intellectual disability (XLID) (eg, syndromic and non-syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2	10/11/2017	11/02/2026
81490	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score	10/11/2017	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
81493	Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score	4/11/2017	11/02/2026
81500	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score	10/11/2017	11/02/2026
81503	Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin, and pre-albumin), utilizing serum, algorithm reported as a risk score	11/02/2026	11/02/2026
81504	Oncology (tissue of origin), microarray gene expression profiling of > 2000 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as tissue similarity scores	10/11/2017	11/02/2026
81525	Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score	10/11/2017	11/02/2026
81529	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis	5/02/2023	11/02/2026
81535	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination	10/11/2017	11/02/2026
81536	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure)	10/11/2017	11/02/2026
81540	Oncology (tumor of unknown origin), mRNA, gene expression profiling by real-time RT-PCR of 92 genes (87 content and 5 housekeeping) to classify tumor into main cancer type and subtype, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a probability of a predicted main cancer type and subtype	10/11/2017	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
82107	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio) [AFP-L3 (Alpha-Fetoprotien L3)]	10/11/2017	11/02/2026
82387	Cathepsin-D	10/11/2017	11/02/2026
82777	Galectin-3	4/11/2017	11/02/2026
83006	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)	4/11/2017	11/02/2026
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2)	4/11/2017	11/02/2026
83700	Lipoprotein, blood; electrophoretic separation and quantitation	4/11/2017	11/02/2026
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation)	4/11/2017	11/02/2026
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed	4/11/2017	11/02/2026
83719	Lipoprotein, direct measurement; VLDL cholesterol	1/18/2018	11/02/2026
83951	Oncoprotein; des-gamma-carboxy-prothrombin (DCP)	10/11/2017	11/02/2026
83987	pH; exhaled breath condensate	1/18/2018	11/02/2026
84112	Evaluation of cervicovaginal fluid for specific amniotic fluid protein(s) (eg, placental alpha microglobulin-1 [PAMG-1], placental protein 12 [PP12], alpha-fetoprotein), qualitative, each specimen	4/11/2017	11/02/2026
84431	Thromboxane metabolite(s), including thromboxane if performed, urine	1/18/2018	11/02/2026
85547	Mechanical fragility, RBC	1/18/2018	11/02/2026
86001	Allergen specific IgG quantitative or semiquantitative, each allergen	4/11/2017	11/02/2026
86152	Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood)	4/11/2017	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
86153	Cell enumeration using immunologic selection and identification in fluid specimen (eg, circulating tumor cells in blood); physician interpretation and report, when required	4/11/2017	11/02/2026
86305	Human epididymis protein 4 (HE4)	4/11/2017	11/02/2026
86343	Leukocyte histamine release test (LHR)	4/11/2017	11/02/2026
86677	Antibody; Helicobacter pylori	4/11/2017	11/02/2026
87623	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (eg, 6, 11, 42, 43, 44)	4/11/2017	11/02/2026
91020	Gastric motility (manometric) studies	1/18/2018	11/02/2026
91022	Duodenal motility (manometric) study	1/18/2018	11/02/2026
91111	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with interpretation and report	11/01/2024	11/02/2026
91112	Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report	4/11/2017	11/02/2026
91117	Colon motility (manometric) study, minimum 6 hours continuous recording (including provocation tests, eg, meal, intracolonic balloon distension, pharmacologic agents, if performed), with interpretation and report	1/18/2018	11/02/2026
91132	Electrogastrography, diagnostic, transcutaneous	1/18/2018	11/02/2026
91133	Electrogastrography, diagnostic, transcutaneous; with provocative testing	4/27/2020	11/02/2026
92145	Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report	4/11/2017	11/02/2026
92548	Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report	4/11/2017	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
92549	Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)	11/02/2026	11/02/2026
93050	Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive	1/18/2018	11/02/2026
93278	Signal-averaged electrocardiography (SAECG), with or without ECG	4/11/2017	11/02/2026
93701	Bioimpedance-derived physiologic cardiovascular analysis	11/01/2024	11/02/2026
93740	Temperature gradient studies	4/15/2019	11/02/2026
95056	Photo tests	1/18/2018	11/02/2026
95065	Direct nasal mucous membrane test	1/18/2018	11/02/2026
95905	Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report	4/11/2017	11/02/2026
96000	Comprehensive computer-based motion analysis by video-taping and 3D kinematics	1/18/2018	11/02/2026
96001	Comprehensive computer-based motion analysis by video-taping and 3D kinematics; with dynamic plantar pressure measurements during walking	1/18/2018	11/02/2026
96002	Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
96004	Review and interpretation by physician or other qualified health care professional of comprehensive computer-based motion analysis, dynamic plantar pressure measurements, dynamic surface electromyography during walking or other functional activities, and dynamic fine wire electromyography, with written report	1/18/2018	11/02/2026
97533	Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes	4/11/2017	11/02/2026
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day	1/18/2018	11/02/2026
A4639	Replacement pad for infrared heating pad system, each	1/18/2018	11/02/2026
A6000	Noncontact wound-warming wound cover for use with the noncontact wound-warming device and warming card	1/18/2018	11/02/2026
A7023	Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical	11/01/2024	11/02/2026
A9291	Prescription digital cognitive and/or behavioral therapy, fda cleared, per course of treatment	5/02/2023	11/02/2026
C1821	Interspinous process distraction device (implantable)	4/11/2017	11/02/2026
C2614	Probe, percutaneous lumbar discectomy	1/18/2018	11/02/2026
C2624	Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components	1/18/2018	11/02/2026
C9359	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Putty, Integra OS Osteoconductive Scaffold Putty), per 0.5 cc	1/18/2018	11/02/2026
C9362	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Strip), per 0.5 cc	1/18/2018	11/02/2026
C9727	Insertion of implants into the soft palate; minimum of three implants	4/11/2017	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
E0218	Fluid circulating cold pad with pump, any type	4/11/2017	11/02/2026
E0221	Infrared heating pad system	1/18/2018	11/02/2026
E0231	Noncontact wound-warming device (temperature control unit, AC adapter and power cord) for use with warming card and wound cover	1/18/2018	11/02/2026
E0232	Warming card for use with the noncontact wound-warming device and noncontact wound-warming wound cover	1/18/2018	11/02/2026
E0236	Pump for water circulating pad	11/01/2024	11/02/2026
E0530	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type	11/02/2026	11/02/2026
E0744	Neuromuscular stimulator for scoliosis	1/18/2018	11/02/2026
E0755	Electronic salivary reflex stimulator (intraoral/noninvasive)	1/18/2018	11/02/2026
E0765	FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting	1/18/2018	11/02/2026
E0849	Traction equipment, cervical, free-standing stand/frame, pneumatic, applying traction force to other than mandible	4/11/2017	11/02/2026
E0850	Traction stand, free-standing, cervical traction	4/11/2017	11/02/2026
E0935	Continuous passive motion exercise device for use on knee only	1/18/2018	11/02/2026
E0936	Continuous passive motion exercise device for use other than knee	1/18/2018	11/02/2026
E1800	Dynamic adjustable elbow extension/flexion device, includes soft interface material	4/11/2017	11/02/2026
E1801	Static progressive stretch elbow device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	1/18/2018	11/02/2026
E1802	Dynamic adjustable forearm pronation/supination device, includes soft interface material	1/18/2018	11/02/2026
E1805	Dynamic adjustable wrist extension/flexion device, includes soft interface material	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
E1806	Static progressive stretch wrist device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories	1/18/2018	11/02/2026
E1810	Dynamic adjustable knee extension/flexion device, includes soft interface material	4/11/2017	11/02/2026
E1811	Static progressive stretch knee device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	1/18/2018	11/02/2026
E1812	Dynamic knee, extension/flexion device with active resistance control	1/18/2018	11/02/2026
E1815	Dynamic adjustable ankle extension/flexion device, includes soft interface material	1/18/2018	11/02/2026
E1816	Static progressive stretch ankle device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories	1/18/2018	11/02/2026
E1818	Static progressive stretch forearm pronation/supination device, with or without range of motion adjustment, includes all components and accessories	1/18/2018	11/02/2026
E1820	Replacement soft interface material, dynamic adjustable extension/flexion device	4/27/2020	11/02/2026
E1821	Replacement soft interface material/cuffs for bi-directional static progressive stretch device	1/18/2018	11/02/2026
E1830	Dynamic adjustable toe extension/flexion device, includes soft interface material	4/11/2017	11/02/2026
E1831	Static progressive stretch toe device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	1/18/2018	11/02/2026
E1840	Dynamic adjustable shoulder flexion/abduction/rotation device, includes soft interface material	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
E1841	Static progressive stretch/patient actualized serial stretch shoulder device, with or without range of motion adjustment, includes all components and accessories	1/18/2018	11/02/2026
E2120	Pulse generator system for tympanic treatment of inner ear endolymphatic fluid	1/18/2018	11/02/2026
G0130	Single energy x-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel)	4/11/2017	11/02/2026
G0255	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve	1/18/2018	11/02/2026
G0295	Electromagnetic therapy, to one or more areas, for wound care other than described in G0329 or for other uses	1/18/2018	11/02/2026
G0329	Electromagnetic therapy, to one or more areas for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care	1/18/2018	11/02/2026
G0460	Autologous platelet rich plasma (PRP) or other blood-derived product for nondiabetic chronic wounds/ulcers (includes, as applicable: administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)	1/18/2018	11/02/2026
G9147	Outpatient Intravenous Insulin Treatment (OIVIT) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea nitrogen (UUN); and/or, arterial, venous or capillary glucose; and/or potassium concentration	1/18/2018	11/02/2026
J1726	Injection, hydroxyprogesterone caproate, (Makena), 10 mg	5/02/2023	11/02/2026
J1729	Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg	5/02/2023	11/02/2026
L3904	Wrist-hand-finger orthosis (WHFO), external powered, electric, custom fabricated	11/01/2024	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
L5973	Endoskeletal ankle foot system, microprocessor controlled feature, dorsiflexion and/or plantar flexion control, includes power source	4/11/2017	11/02/2026
L5990	Addition to lower extremity prosthesis, user adjustable heel height	1/18/2018	11/02/2026
L6026	Transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device, excludes terminal device(s)	1/18/2018	11/02/2026
L6895	Addition to upper extremity prosthesis, glove for terminal device, any material, custom fabricated	1/18/2018	11/02/2026
P2028	Cephalin flocculation, blood	11/01/2024	11/02/2026
P2031	Hair analysis (excluding arsenic)	11/01/2024	11/02/2026
P2033	Thymol turbidity, blood	1/18/2018	11/02/2026
P2038	Mucoprotein, blood (seromucoid) (medical necessity procedure)	1/18/2018	11/02/2026
S0596	Phakic intraocular lens for correction of refractive error	1/18/2018	11/02/2026
S2080	Laser-assisted uvulopalatoplasty (LAUP)	4/11/2017	11/02/2026
S2103	Adrenal tissue transplant to brain	1/18/2018	11/02/2026
S2117	Arthroereisis, subtalar	1/18/2018	11/02/2026
S2300	Arthroscopy, shoulder, surgical; with thermally-induced capsulorrhaphy	1/18/2018	11/02/2026
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar	1/18/2018	11/02/2026
S3652	Saliva test, hormone level; to assess preterm labor risk	1/18/2018	11/02/2026
S3865	Comprehensive gene sequence analysis for hypertrophic cardiomyopathy	1/18/2018	11/02/2026
S3900	Surface electromyography (EMG)	1/18/2018	11/02/2026
S3902	Ballistocardiogram	1/18/2018	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
S9056	Coma stimulation per diem	1/18/2018	11/02/2026
S9986	Not medically necessary service (patient is aware that service not medically necessary)	4/27/2020	11/02/2026
No specific code - may be billed with an unlisted code	Biodesign® (formerly Surgisis®) Anal Fistula Plug Set	11/02/2026	11/02/2026
No specific code - may be billed with an unlisted code	Biodesign® (formerly Surgisis®) Hiatal Hernia Graft	11/02/2026	11/02/2026
No specific code - may be billed with an unlisted code	CartiMax® Viable Cartilage Allograft	11/02/2026	11/02/2026
No specific code - may be billed with an unlisted code	Endobon® Xenograft Granules	11/02/2026	11/02/2026
No specific code - may be billed with an unlisted code	GORE® Seamguard® Bioabsorbable Staple Line Reinforcement	11/02/2026	11/02/2026
No specific code - may be billed with an unlisted code	Grafton™ Crunch DBM	11/01/2025	11/02/2026
	Grafton™ DBF		
	Grafton™ Matrix		
	Grafton™ Orthoblend-large		
	Grafton™ Orthoblend-small		
	Grafton™ Paste		
	Grafton™ Putty		
	Grafton™ Strips		
No specific code - may be billed with an unlisted code	GraftRope™	11/02/2026	11/02/2026

Table 1			
The following services are considered experimental, investigational, or unproven and are therefore NOT covered:			
<i>Code</i>	<i>Description</i>	<i>Date Added</i>	<i>Last Review Date</i>
No specific code - may be billed with an unlisted code	PTFE felt	11/02/2026	11/02/2026
No specific code - may be billed with an unlisted code	Ventrio™ ST Hernia Patch	11/02/2026	11/02/2026

Clinical Guideline Revision / History Information

Original Date: 4/11/2017

Reviewed/Revised: 10/11/2017, 1/18/2018, 4/15/2019, 5/05/2020, 7/21/2020, 04/21/2021, 12/01/2021, 04/25/2022, 05/02/2023, 11/01/2024, 11/01/2025, 11/02/2026